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Background: The role of argininosuccinate 
lyase (ASL) transcripts in disease variability is 
unclear. 
Results: The most common ASL transcript 
variants decrease the functional enzymatic 
activity after co-expression with wildtype or 
mutant ASL.  
Conclusion: ASL transcripts expressed at high 
levels can contribute to the variable phenotype in 
ASL-deficient patients. 
Significance: A new explanation of molecular 
basis adds to our understanding of the clinical 
variability in patients. 
 
 
Abstract 
 
Argininosuccinic aciduria (ASA) is an 
autosomal recessive urea cycle disorder 
caused by deficiency of argininosuccinate 
lyase (ASL) with a wide clinical spectrum 
from asymptomatic to severe 
hyperammonemic neonatal onset life-
threatening courses. We investigated the role 
of ASL transcript variants in the clinical and 
biochemical variability of ASA. Recombinant 
proteins for ASL wildtype, mutant 
p.Glu189Gly and the frequently occurring 
transcript variants with exon 2 or 7 deletions 
were (co)-expressed in human embryonic 
kidney 293T cells. We found that exon 2-
deleted ASL forms a stable truncated protein 
with no relevant activity but a dose-
dependent dominant negative effect on 
enzymatic activity after co-expression with 
wildtype or mutant ASL, while exon 7-deleted 
ASL is unstable but seems to have, 
nevertheless, a dominant negative effect on 
mutant ASL. These findings were supported 
by structural modelling predictions for ASL 
hetero/homotetramer formation. Illustrating 
the physiological relevance, the predominant 
occurrence of exon 7-deleted ASL was found 
in two patients who were both heterozygous 
for the ASL mutant p.Glu189Gly. Our results 
suggest that ASL transcripts can contribute 
to the highly variable phenotype in ASA 
patients if expressed at high levels. Especially, 
the exon 2-deleted ASL variant may form a 
heterotetramer with wildtype or mutant ASL 
causing markedly reduced ASL activity.   
 
 
Introduction 
 
Argininosuccinate lyase (ASL; EC 4.3.2.1; 
OMIM *608310) catalyzes the reversible 
hydrolytic cleavage of argininosuccinate into 
arginine and fumarate and contributes to 
removal of waste nitrogen and biosynthesis of 
arginine within the urea cycle in ureotelic 
species (1). ASL is also involved in the arginine-
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citrulline cycle as part of a multi-protein 
complex required for production of nitric oxide 
(2) as well as in other pathways (Fig. 1).   
The human ASL gene is located on chromosome 
7q11.21 (3-4) and comprises 16 exons encoding 
464 amino acids (5-6). The resulting monomers 
have a predicted molecular mass of ~52 kDa and 
form a homotetrameric functional enzyme with 
four active sites (7). ASL has significant 
homology to δ-crystallin with an amino acid 
sequence identity of 64-71% between human 
ASL and various δ-crystallins (8-9). The δ-
crystallins are major structural components of 
avian and reptilian eye lenses and show 
significant ASL enzyme activity in duck and 
chicken (9-10). Human ASL is expressed 
predominantly in liver (11) but is also detected 
in many other tissues including kidney (12), 
small intestine (13-14), pancreas and muscle 
(15), heart (16), brain (17-18), skin fibroblasts 
(19) and erythrocytes (20).   
Mutations in the ASL gene result in an autosomal 
recessive disorder known as argininosuccinic 
aciduria (ASA; synonymous ASL deficiency, 
ASLD; OMIM #207900) (21) which is the 
second most common disorder in the urea cycle 
with an estimated incidence of approximately 1 
per 70,000 live births (22). The clinical and 
biochemical phenotype of ASA is highly 
variable ranging from asymptomatic cases with 
only a biochemical phenotype (23-25), some of 
them diagnosed through newborn screening, to 
severe neonatal-onset hyperammonemic 
encephalopathy (26-27). The molecular basis for 
the diversity of ASA is not fully understood and 
several explanations have been suggested 
including tissue specific ASL expression (27-
28), genetic heterogeneity at the ASL locus (29), 
intragenic complementation (7,30-32), different 
levels of residual ASL activity (33-34), the 
developmental control of the ASL gene by DNA 
methylation (35), and alternative splicing events 
at the ASL locus leading to frequent exon 
deletions (5,36-37).  
In this study we explored the role of naturally 
occurring ASL transcript variants in the 
formation and function of ASL homotetramer to 
better understand the phenotypic variability of 
ASA. By combining computational structural 
analysis using molecular dynamic simulations 
and eukaryotic (co-)expression of wildtype (wt) 
with the most common transcript variants 
formed by deletions of exons 2 or 7, we could 
show that exon 2-deleted (ex2del) or exon 7-
deleted (ex7del) ASL has a dominant negative 
effect on the ASL activity after co-expression 
with wildtype or mutant ASL, respectively. 
Suggesting a physiological role of transcript 
variants, RNA analysis revealed a predominant 
expression of ex7del ASL in two ASA patients 
identified with heterozygous for the ASL mutant 
p.Glu189Gly. Taken together, these findings 
suggest that the frequent occurrence of ASL 
transcript variants, when they are expressed at 
high levels, can be a factor contributing to the 
highly variable clinical and biochemical 
phenotype of ASA. In particular, the effect may 
be even more striking in the stable mutant such 
as ex2del ASL variant since it may form a 
heterotetramer with ASL wildtype or naturally 
occurring missense mutations (i.e. sequence 
alterations with a disease-causing role found in 
ASL deficient patients) contributing to reduced 
ASL activity.  
 
 
Experimental Procedures 
 
ASL transcript expression in different tissues  
A panel of cDNAs from 17 different human 
tissues comprising ASL patient fibroblasts and 
16 other tissues (Multiple Tissue cDNA Panel 
Human I and II, Clontech, Mountain View CA, 
USA) was used for the amplification of full-
length ASL as well as shorter RNA fragments. 
In addition, short ASL cDNA fragments derived 
from skin fibroblasts of 24 ASA patients with 10 
different genotypes were amplified. Specific 
oligonucleotides ASL-FL-F-
5’acgaggaaccgcccaacat3’ (forward) and ASL-
FL-R-5’tgcctctccagtccctgactgt3’ (reverse) were 
used for amplification of full-length ASL; 
primers ASL-SF-F-5’acactatccgtgcggccagg3’ 
(forward, derived from ASL 5’-UTR-sequence) 
and ASL-SF-R-5’tgagatgggtcatgcacagcg3’ 
(reverse, derived from ASL exon 10 sequence) 
were used for amplification of a short fragment 
containing exons 1-9 with a fragment size of 864 
bp. Hot start PCR was performed at an annealing 
temperature of 60oC (62oC for primers ASL-SF-
F with ASL-SF-R)  for 38 cycles (42 cycles for 
primers ASL-SF-F with ASL-SF-R) using HOT 
FIREPol® DNA polymerase (Solis Biodyne, 
Tartu, Estonia) or HotStarTaq DNA Polymerase 
(QIAGEN GmbH, Hilden, Germany) prior to gel 
electrophoresis. PCR products representing 
probable splice variants were confirmed by 
sequencing using the BigDye Terminator cycle 
sequencing kit V.1.1 (Applied Biosystems, ABI 
sequence).  
Patients or their legal guardians had consented to 
the use of the cultured skin fibroblasts for 
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research purposes when the skin biopsy was 
taken and cDNA samples were anonymized 
prior to their use in this study. 
 
Patients’ characteristics and RNA studies 
The 19-year-old male patient, offspring of non- 
consanguineous parents, was first identified at 
the age of 13 years with mild hyperammonemia 
(250 µmol/L, normal <50), confusion and 
irritability during an episode of gastroenteritis. 
The diagnosis of ASA was made based on 
characteristic urine metabolites and underlined 
by typical signs and symptoms such as mild 
hepatomegaly but normal liver function, 
trichorrhexis nodosa, cognitive impairment (IQ 
67), and a natural avoidance of protein rich food 
since early childhood. Besides, there was 
persistent mild elevation of plasma citrulline 
(between 80 and 150 µmol/L, normal <60). 
Under treatment with L-arginine (150 mg/kg 
/day) and mild protein restriction he was stable 
ever since apart from a single mild metabolic 
decompensation at age 17 years again during 
gastroenteritis with maximum ammonia (230 
µmol/L). 
To confirm the diagnosis, DNA sequencing of 
the ASL gene by standard methods (6) as well as 
array comparative genomic hybridization (38) 
for exclusion of a deletion on the second allele 
revealed only a single heterozygous mutation in 
exon 7 (c.566A>G, p.Glu189Gly) which was not 
present on the maternal allele (also, no other 
mutation was found in the mother in DNA or 
RNA) while the mutation was found in a 
heterozygous state in paternal DNA. To identify 
the second mutant allele, RT-PCR was 
performed using RNA (PrimeScript II 1st Strand 
cDNA Synthesis kit, TaKaRa Bio) derived from 
a 3-days full blood culture treated with 
phytohemagglutinin and cycloheximide (39). For 
control-RT-PCR, cDNAs derived from 
lymphocytes, liver and fibroblasts were used. 
The patient’s cDNA was amplified in ASL full 
length as well as in a short fragment comprising 
exons 1 to 9 as described above. In addition, 
primers ASL-SF-F and ASL-SF-R7-
5’ctccccaggggcaggacattg3’ (reverse, derived 
from ASL exon 7 sequence) were used for 
amplification of a short fragment containing 
exons 1-7 (fragment size of 670 bp) to confirm 
mutation c.566A>G in this transcript. PCR 
products were sequenced as described above. 
In another patient (aged 12 years) with late onset 
ASA and a similar clinical and biochemical 
situation, the mutation p.Glu189Gly was found 
in a heterozygous state and the same DNA and 
RNA investigations were performed as above. 
To estimate expression levels of transcripts, 
densitometry analysis of RT-PCR products on 
gel electrophoresis and of bands detected by 
Western blotting was performed by using 
Carestream Molecular Imaging software 
(Carestream Health, Germany). 
The genetic studies were done after written 
informed consent of the patient and his legal 
guardians was obtained. 
 
Generation of wildtype, mutant ASL 
p.Glu189Gly and exon 2 or 7 deleted splice 
variant constructs 
Full-length ASL cDNA (1395 bp) and ex7del 
ASL transcript variant (1317 bp) were cut from 
pCR2.1 carrying the wt ASL (33) and pCMV6-
XL4 carrying the ex7del ASL cDNA (OriGene, 
Rockville, MD, USA) using restriction enzymes 
BamHI and NotI (both New England Biolabs, 
Beverly, MA, USA), respectively. Restriction 
products were cloned into the expression vector 
pcDNA3 (Invitrogen, Carlsbad, CA, USA) 
yielding pcDNA3-ASL-wt (P-wt) and pcDNA3-
ASL-ex7del (P-ex7del), respectively. 
Oligonucleotides ASL-ex2del-F-
5’atccggatccatggcctcggaggtggctgaggagtgggcc3’ 
(forward, consisting of a BamHI site, the 12 
nucleotides (nt) of ASL exon 1 and 18 nt from 5’ 
exon 3) and ASL-ex2del-R-
5’cctctagatgcatgctcgagcggccgctatatctaggc3’ 
(reverse, with a NotI site added to an ASL 3’-
UTR-sequence) were used to amplify the exon2-
deleted ASL cDNA from P-wt. The obtained 
PCR product was gel-purified and cloned into 
the above expression vector yielding pcDNA3-
ASL-ex2del (P-ex2del). The mutant 
p.Glu189Gly (c.566A>G) was constructed as 
pcDNA3-ASL-Glu189Gly (P-E189G) based on 
P-wt by site-directed mutagenesis (Phusion Site-
directed mutagenesis Kit, Finnzymes, Espoo, 
Finland) according to manufacturer’s protocol. 
All established constructs were confirmed by 
sequencing as above. 
 
Expression and co-expression of ASL constructs 
in human embryonic kidney 293T cells  
Three different mammalian cell lines (COS-1, 
HeLa and 293T) were tested for their 
background ASL activity before establishing the 
eukaryotic ASL expression system. ASL 
expression levels after transfection with P-wt 
were determined by Western blot. Cells were 
grown in Dulbecco’s modified Eagle’s medium 
+ GlutaMAX (DMEM, Gibco, Paisley, UK) 
 3
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
                                                                                                    Role of ASL Transcript Variants in ASA 
supplemented with 10% fetal bovine serum 
(FBS) and 1% antibiotic/antimycotic solution 
(both PAA, Pasching, Austria) and maintained in 
an incubator containing 5% CO2 at 37oC in a 
humidified atmosphere.   
Based on the lowest ASL background activity, 
293T cells were considered as ideal for the ASL 
expression system in this study. The cells were 
transiently (48 hours) transfected with total 7 µg 
of the constructs P-wt, P-ex2del or P-ex7del in 
60 mm dishes using Lipofectamine™ LTX and 
PLUS™ reagents according to the 
manufacturer’s instructions (Invitrogen, Basel, 
Switzerland). Total 7 µg or 10.5 µg of plasmids 
were used for co-transfection with 2 or 3 
plasmids; if not indicated otherwise, we used the 
same amount of respective constructs (each 3.5 
µg) in co-transfectants. For the co-transfection 
of P-wt and P-ex2del at different ratios, 1.75 µg 
P-wt and 1.75 µg P-ex2del was used for the ratio 
1:1; 1.75 µg P-wt and 3.5 µg P-ex2del for 1:2;  
1.75 µg P-wt and 8.75 µg P-ex2del for 1:5; 3.5 
µg P-wt and 1.75 µg P-ex2del for 2:1; 8.75 µg 
P-wt and 1.75 µg P-ex2del for 5:1. The empty 
vector (EV) pcDNA3 was used either as 
negative control or to set up same amounts of 
total plasmids for co-transfection.  
RNA was isolated from the cells transiently 
transfected with P-wt, P-ex2del or P-ex7del, 
respectively, using QIAamp RNA blood minikit 
according to the manufacturer’s protocol 
(QIAGEN GmbH, Hilden, Germany). The 
concentration of nucleic acids was determined 
by Nanodrop. RT-PCR was performed as 
standard protocol using primers ASL-SF-F3-
5’atccacacagccaatgagcgc3’ (forward, derived 
from ASL exon 3 sequence) and ASL-SF-R for 
amplification of a short fragment containing 
exons 4-9 with a fragment size of 535 bp. 
 
Protein extraction, Western blot analysis and 
Immunoprecipitation 
Cells were harvested and lysed in Lubrol WX 
lysis buffer containing 0.15% (w/v) of Lubrol 
WX (Sigma Chemical Co., Poole, Dorset, UK) 
and 10 mM of Tris-HCl (pH 8.6). Human liver 
tissue (n=3, shock frozen needle biopsy samples 
for diagnostic purposes in non ASLD patients 
after informed consent into scientific use was 
obtained) was homogenized in complete Nonidet 
P40 (NP-40, Roche Diagnostics GmbH, 
Mannheim, Germany) lysis buffer containing 
1% of NP-40, 50 mM of Tris-HCl (pH 8), 125 
mM of NaCl, 1 mM of 
Ethylenediaminetetraacetic acid (EDTA) and 
protease inhibitors (1x Complete EDTA-free + 1 
mM of phenylmenthy-sulfonyl fluoride, PMSF) 
(Roche Diagnostics GmbH, Mannheim, 
Germany) in a pre-chilled glas-grinder by 
quickly grinding on ice. Cell lysates and liver 
homogenates were then centrifuged at maximum 
speed at 4oC for 15 min. Protein concentrations 
in the supernatants (= cell extracts) were 
determined by the method of Lowry (40) using 
bovine serum albumin (BSA) as a standard.   
Western blotting was performed as previously 
described (41). 30 µg total protein of cell 
extracts was separated by 10% denaturing 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) or native PAGE 
(without SDS in the Laemmli loading buffer and 
electrophoresis buffer), and subsequently 
transferred to nitrocellulose transfer membranes 
(Whatman GmbH, Dassel, Germany). The 
primary polyclonal antibody anti-ASL 
(GeneTex, Irvine CA, USA), recognizing ASL 
residues 13 to 261 according to the 
manufacturer, was used at a dilution of 1:1000 
and the horseradish peroxidase (HRP)-
conjugated secondary antibody anti-rabbit (Santa 
Cruz Biotechnology, Santa Cruz CA, USA) was 
used at a dilution of 1:5000. Antibodies against 
β-actin or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (both Santa Cruz 
Biotechnology) served as loading controls. 
Protein detection was done using ECL reagents 
(GE Healthcare, Glattbrugg, Switzerland) for 
chemiluminescent labelling.  
Fibroblasts derived from 3 ASA patients as well 
as one control were cultured under the same 
condition as for 293T cells. Immunoprecipitation 
analysis was done as standard protocol using 5 
mg of total protein of fibroblasts followed by 
Western blot analysis as described above. HRP-
conjugated Mouse Anti-rabbit IgG (L27A9, Cell 
Signaling Technology, Inc. Danvers, USA), 
which does not recognize the denatured and 
reduced rabbit IgG heavy or light chains on 
Western blot, was used as secondary antibody at 
a working dilution of 1:2000.   
 
Measurement of ASL enzymatic activity 
The ASL enzyme activity was determined 
spectrophotometrically in cell extracts after 
transient transfection or co-transfection of P-wt, 
P-ex2del and/or P-ex7del, using a coupled assay 
with arginase and measuring urea production as 
described before (33). Briefly, 100 µl of 34 mM 
argininosuccinate (argininosuccinic acid 
disodium salt hydrate) in water and 100 µl 
arginase (50 units) (both Sigma-Aldrich, Buchs, 
Switzerland) in 66.7 mM phosphate buffer (11.1 
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mM potassium dihydrogenphosphate and 55.6 
mM disodium hydrogenphosphate, pH 7.5) were 
incubated at 37oC for 5 min. Then 40 µl cell 
extract (3-14 µg total protein) and 10 µl 
phosphate buffer were incubated with the above 
reagents at 37oC for 30 min. The reaction was 
stopped by adding perchloric acid at a final 
concentration of 2%. The ASL enzyme activities 
are given as mIE/mg total protein. The residual 
ASL activities of splicing variants are 
determined as percentage of ASL-wt or ASL-wt 
with EV activity (%) in each (co-)transfection 
under same condition, respectively. All assays 
were carried out in triplicate for at least 3 
independent co-transfection experiments.  
 
Structure modelling  
3D protein model and in-silico mutagenesis of 
ASL – The tetrameric 3D structural model of 
ASL (NCBI NP_000039.2, Uniprot P04424) 
sequence (AA 1-464) was built using the ASL 
structure (1K62) as template. Model building 
was performed with programs YASARA (42) 
and WHATIF (43). Side chains in newly built 
parts were optimized by molecular dynamic 
(MD) simulations. The geometry information for 
the tetramer was extracted from the original 
crystallographic data. The final model was 
refined by a 1000 ps (MD) simulation using 
AMBER 2003 force field and checked with the 
programs WHAT_CHECK (44), WHATIF (43), 
Verify3D (45-46), and Ramachandran plot 
analysis (47-48). To create the exon 2 and exon 
7 deletions we first made the FASTA sequence 
files of modified proteins and performed model 
building using both the monomer and tetramer 
structures and performed refinements as 
described for wt protein. Structures were 
depicted with Pymol (www.pymol.org). 
Structural properties of the proteins were 
calculated by YASARA and WHATIF and 
general protein parameters were calculated with 
Expasy protein tools (www.expasy.ch) 
 
Molecular Dynamics simulation for model 
refinement - The MD simulations were 
performed using AMBER03 force field (42). 
The simulation cell was filled with water, pH 
was fixed to 7.4 and the AMBER03 (49) 
electrostatic potentials were evaluated for water 
molecules in the simulation cell and adjusted by 
addition of sodium and chloride ions. The final 
MD simulations were then run with AMBER03 
force field at 298K, 0.9% NaCl and pH 7.4 for 
1000 ps to refine the models. Best models were 
selected for analysis and evaluation of the effect 
of exon deletions on monomer and tetramer 
structures. 
 
Statistics 
Statistical analyses were done using percentages 
of ASL-wt activities by One-way ANOVA with 
the program GraphPad Prism 4 (GraphPad 
Software, San Diego, CA) to describe the 
differences of ASL activities between cells co-
expressing ASL-wt with EV and cells co-
expressing ASL-wt with the transcript variants. 
Differences were considered as significant if p 
value was < 0.05. 
 
 
Results 
 
Expression of wildtype ASL and of transcript 
variants in different tissues  
To investigate whether the expression of ASL 
transcript variants is tissue-dependent and to 
confirm the reported occurrence of transcripts 
with deletions of exon 2 or 7 (5,36-37), we 
amplified ASL cDNA either in full-length (Data 
not shown) or in short cDNA fragments 
comprising exons 1-9 from 17 different human 
tissues (only 16 tissues shown in Fig. 2A) and a 
series of 24 skin fibroblast cell lines from ASA 
patients representing 10 different genotypes 
(Fig. 2B). In all tissues, wt ASL cDNA (short 
fragment with 864 bp) and, in addition in most 
tissues shorter transcript variants (786 bp, 669 
bp) could be detected (Fig. 2A,B). ASL-wt 
cDNA was predominantly found in liver (Fig. 
2A: lane 5) and kidney (Fig. 2A: lane 7), but 
expression was detected in all tissues. 
Furthermore, a similar expression pattern of 
ASL transcript variants was detected at low level 
in all cDNAs investigated for short fragments 
(Fig. 2A,B). Sequencing analysis of the shorter 
fragments identified them as exon 2- (669 bp) or 
exon 7-deleted (786 bp) transcripts. 
 
RNA studies reveal predominant expression of 
exon 7-deleted ASL transcript variant in ASA 
patients 
In RNA from both patients, ASL-ex7del variant 
(786 bp) was predominantly expressed (Fig. 2C: 
lane 2, 3; Fig. 2D: lane 16). Estimation of 
expression levels by densitometry yielded 
similar levels of the mutant variant (114% for 
Fig. 2C: lane 2 and 83% for Fig. 2C: lane 3) 
when compared to wt ASL (864 bp) in 
lymphocyte control (Fig. 2C: lane 4, set to 
100%) but much higher levels (330% for Fig. 
2C: lane 2 and 182% for Fig. 2C: lane 3) if 
 5
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
                                                                                                    Role of ASL Transcript Variants in ASA 
compared with the full-length band in the same 
patients (Fig. 2C: lane 2 and 3, set to 100%). 
Notably, the full-length band was expressed 
much less (34% for Fig. 2C: lane 2 and 46% for 
Fig. 2C: lane 3) compared to wt in lymphocyte 
control (Fig. 2C: lane 4, set to 100%). 
Expression levels of transcript variants in 
controls (Fig. 2C: lane 4; Fig. 2D: lane 1-15) and 
also in the patient’s mother (Fig. 2C: lane 1; Fig. 
2D: lane 17) were much lower in all tissues 
compared to wt (lymphocytes 9%, liver 6%, 
fibroblasts 10% as shown in Fig. 2D lanes 1-5, 
6-10, 11-15, respectively). Sequencing 
confirmed that the variants represented ex2del or 
ex7del transcripts. To facilitate further 
sequencing, only a small fragment comprising 
exons 1-7 was amplified using a reverse primer 
derived from exon 7. Hereby, the mutation 
c.566A>G was confirmed in a hemizygous state 
in one patient (Fig. 2C: lane 2; Fig. 2E) and in a 
heterozygous state in the other patient (Fig. 2C: 
lane 3; Fig. 2F).  
 
Endogenous ASL expression in mammalian cell 
lines and in human liver 
To establish an ASL expression system in 
mammalian cells lacking endogenous but 
allowing for high ectopic ASL expression, we 
transiently transfected P-wt as well as EV 
pcDNA3 into COS-1, 293T and HeLa cells, 
respectively. Western blot analysis indicated that 
293T cells fulfilled the above criteria in an 
optimal way while COS-1 cells showed 
endogenous ASL expression and HeLa cells 
failed to express ASL after transfection (Fig. 
3A). These results were further confirmed by 
analysis of ASL activity (ASL endogenous 
activity in 293T cells shown in Table 1).  
Although ASL splice variants (ASL-ex7del and 
ASL-ex2del) were present in all cDNAs from 
various tissues (Fig. 2A-D), there was no 
corresponding signal detected when human liver 
homogenates from controls were investigated by 
Western blot analysis (Fig. 3B). Likewise, 
immunoprecipitation did not yield a detectable 
wt signal when patients’ and control fibroblasts 
were used (Data not shown). This points towards 
and is probably explained by the low level of 
ASL expression in this cell type which is 
obviously not suited for further investigation of 
ASL wildtype and mutants on the protein level.  
 
Expression and co-expression of ASL wildtype, 
mutant and transcript variants in 293T cells  
To study the role of naturally occurring ASL 
splice variants in wildtype as well as in mutant 
p.Glu189Gly, we first introduced diverse ASL 
recombinant constructs P-wt, P-E189G, P-
ex2del and P-ex7del into 293T cells to (co-) 
express ASL wt, mutant p.E189G, ex2del or 
ex7del ASL, respectively. At the protein level, 
expression of ASL-wt or ASL-ex2del was 
detected either as monomers (Fig. 3C: lane 3 and 
4 in upper panel; Fig. 3D: lane 1 and 5 in upper 
panel, respectively) or as homotetramer (Fig. 
3C: lane 3 and 4 in middle panel; Fig. 3E: lane 1 
and 5 in upper panel, respectively). Moreover, 
ASL-ex2del could also be co-expressed with 
ASL-wt as well as with mutant p.E189G (Fig. 
3D-G). Densitometry analysis of the detectable 
bands by Western blotting showed that ASL-wt 
was less expressed  in cells co-expressed with 
transcript variants (71.7% in co-transfectant with 
ASL-ex2del in Fig. 3D: lane 2; 88.7% in co-
transfectant with ASL-ex7del in Fig. 3D: lane 3; 
71.2% in co-transfectant with ASL-ex2del and 
ASL-ex7del in Fig. 3D: lane 4; all done after 
normalisation according to expressed loading 
control GAPDH, respectively) compared to co-
expression with EV (Fig. 3D: lane 1, set to 
100%). Additionally, ASL-ex2del was expressed 
at higher levels (55.4%, 53.6%, 60% or 61%) 
than ASL-wt (44.6%, 46.4% or 40%) or mutant 
p.Glu189Gly (39%) (cells co-transfected with 
ASL-ex2del and ASL-wt in Fig. 3A: lane 2, 4; 
Fig. 3G: lane 4; cells co-transfected with ASL-
ex2del and p.Glu189Gly in Fig. 3G: lane 6). 
However, ASL-ex7del was not found (Fig. 3C: 
lane 5; Fig. 3D,E: lane 6 in upper panel; Fig. 3G: 
lane 9, respectively) although ASL-ex7del-RNA 
derived from cells transfected with P-ex7del 
could be detected by RT-PCR (Data not shown). 
These results suggest that deletion of ASL exon 2 
results in a truncated but stable ASL protein 
while deletion of ASL exon 7 probably leads to 
an unstable protein.  
 
Structure of ASL monomers and homotetramer  
To study the structural implications of exon 2 
and 7 deletions we made computational 
structural models of exon deleted ASL variants 
based on known structures of ASL available 
from RCSB database. We first performed a 
PhiBlast search of PDB database with the 
modified amino acid sequences to create a 
custom position specific scoring matrix (PSSM) 
that was then used in further runs of PhiBlast 
searches to identify structurally similar 
sequences. Then a secondary structure prediction 
of the original wt sequence was used to perform 
the structure based alignment of the sequences 
(Fig. 4). Aligned sequences were loaded in the 
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programs YASARA and WHATIF for 
generating structural models. Some of the loops 
in exon deleted sequences were modelled 
separately by scanning a library of loop 
databases. For our model building we used the 
information available in PDB_REDO database 
(http://swift.cmbi.ru.nl/gv/pdbredo/index.html) 
which re-refines the old structures in PDB 
database using latest methods based on original 
structural data deposited in PDB, and corrects 
the errors in structures found in PDB database. 
This is achieved by employing current state of 
the art refinement methods and software to the 
older crystallographic data. For the ASL 
structure (PDB #1K62), the overall 
Ramachandran plot appearance improved from -
2.514 to -0.803 for the optimized entry, and total 
number of bumps/structural clashes were 
reduced from 150 in the original entry to 54 in 
optimized structure, Chi-1/Chi-2 rotamer 
normality improved from -2.186 to -0.576, 1st 
generation packing quality improved from 0.148 
to 0.466, backbone conformation improved from 
-0.369 to -0.168 and R-free value changed from 
0.2290 to 0.1909 in the fully optimised version 
used by us.  
The ASL structure is composed of residues 5-
464 of ASL protein. The enzymatically active 
ASL tetramer is formed by four identical 
subunits of ASL comprising of mainly alpha 
helices and contains three structurally distinct 
domains. Domains 1 and 3 have similar topology 
and contain two helix-turn-helix motifs while 
domain two has nine helices out of which five 
helices form the core monomer structure in an 
up-down-up-down-up sequence (Figure 5A). 
Two sets of dimers come together in antiparallel 
manner to form the tetramer (Fig. 5A, 6A). The 
core of the homotetramer is composed of a four-
helix bundle with each monomeric subunit 
contributing one helix to the central core, and the 
tetramer is held together by hydrophobic 
interactions between the four central helices as 
well as ionic interactions between arginines and 
glutamic acid residues on two distinct dimeric 
structures. 
 
Role of exon 2 residues 
The amino acid residues contributed by exon 2 
(5-69) form the N-terminus of the ASL protein 
(Fig. 4 and 5A) and are needed for the enzymatic 
activity as the previously described R12Q 
mutation in exon 2 has been shown to result in 
loss of activity. Two of the helices in domain 2 
of ASL monomeric structure are formed by 
residues from exon 2 and are missing in 
exon2del variant of ASL (Fig. 5B). Most of the 
N-terminal chain in the ASL monomer is 
flexible and during molecular dynamic 
simulations it was found to fluctuate during the 
whole run indicating a dynamic arrangement in 
both the monomeric and tetrameric form. There 
were few contacts between the N-terminal loops 
of any individual subunit to other subunits in the 
tetrameric structure, indicating that it probably 
does not influence tetramer formation. The role 
of N-terminus residues on the catalytic activity is 
not clear but one side of the active site is 
covered by these residues (Fig. 6B,C). The 
flexible nature of amino acids 5-18 suggests that 
although exact conformation of the N-terminus 
does not influence the overall tetrameric 
structure or active site of the enzyme (Fig. 
6B,C), the structural requirements for substrate 
binding and retention in the active site may 
depend on an intact N-terminus. Residues 23-32 
of the ASL have been proposed to be important 
for substrate binding (50-51).    
From our computational analysis we found that 
exon 2 deleted protein can form a stable 
monomer (Fig. 5B) and homotetramer (Fig. 6D), 
which was confirmed by western blots showing 
a smaller sized complex from the cell-based 
assays (Fig. 3C-G). However, such a 
homotetramer will be devoid of activity due to 
loss of N-terminal residues needed for substrate 
binding. Therefore, although an exon 2 deleted 
transcript of ASL is still capable of expressing a 
stable monomer which can form a tetrameric 
complex, the loss of residues involved in 
catalysis means such a complex can not be 
enzymatically active. It is possible that ASL-wt 
and ex2del monomers can form heterotetramers 
with different combinations of the two transcript 
variants. Since the active site of the ASL protein 
is formed by contributions from three different 
monomeric subunits, each unit of exon 2 deleted 
transcript variants in the heterotetramer will 
result in loss of one active site, without 
compromising the overall structure. Since the N-
terminal residues affected by deletion of exon 2 
do not participate in the formation of ASL 
dimers, we propose that a combination of wt, 
ex2del and wt-ex2del versions of the dimers is 
generated which will then further oligomerize to 
form the tetrameric structures. Wt and ex2del 
variants of the monomers may have preference 
for similar sized proteins and only form 
homodimers, which will result in at least two 
functional active sites in a 2:2 heterotetramer. 
Functional data from cell based assays which 
show that even 1:5 combination of wt-ex2del 
 7
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
                                                                                                    Role of ASL Transcript Variants in ASA 
ASL retained about 30% activity (Fig. 7C) 
seems to support this model. A combination of 
WT-exon2del dimers may also give similar 
activities.  
 
Role of Exon 7 residues  
Residues 175-200 are contributed by exon 7 in 
the wt ASL transcript. Exon 7 deleted variant 
was found to be capable of forming a 
monomeric structure still composed of three 
distinct domains, similar to that of WT ASL 
(Fig. 5C). While the core of homotetramer of 
ASL is formed by alpha helices of monomers 
formed by residues 291-314, we found ionic 
interactions between adjacent dimeric subunits 
in the tetramer to stabilize the structure (Fig. 
6E,F). From the molecular dynamic simulations 
and structural analysis we found that charge pair 
interactions between R193 on one subunit with 
E189 and E185 of another adjacent subunit in 
the tetramer stabilizes the structure (Fig. 6G). 
The loss of ionic interactions contributed by 
exon 7 residues will result in an unstable 
tetramer. Computational potential energy of WT 
and exon7del tetramers supported this theory 
with an increase in potential energy for the 
exon7del tetramer (-76378 kJ/mol for exon7del 
compared to -95229 kJ/mol for WT) (Table 2). 
Moreover, a change in core structure of the 
monomers was also observed with loss of two 
central helices and formation of a structurally 
unstable loop in the middle of the helical core 
(Fig. 5C, 6G,H). Such a change is likely to 
impact the stability of the monomers and may 
result in an unstable protein which will likely be 
degraded, especially in the absence of a stable 
tetrameric complex. Significantly, due to this 
unstructured loop formation the accessible 
surface area of the ex7del variant increased 
significantly (65259Å2 compared to 53534 Å2 
for the WT) while solvent accessible surface 
remained similar (326476 Å3 compared to 
322934 Å3 for the WT) which further points 
toward structural instability of ex7del variant 
(Table 2). This was also further supported by 
western blots showing no detectable ASL-ex7del 
expression (Fig. 3C-E,G). 
 
Residual ASL enzymatic activities in (co-) 
transfected 293T cell extracts 
To determine whether the expressed ASL splice 
variants have any residual enzyme activity, we 
performed ASL enzyme activity assays with the 
cell extracts used for Western blot analysis 
(summary of data in Table 1, Table 3 and Fig. 
7). There was no relevant background activity in 
cells transfected with the empty vector or non-
transfected cells (Fig. 7A: columns 1 and 2, 
respectively). No significant residual activity 
was detected in exon 2- and exon 7-deleted ASL 
splice variants (Fig. 7A: columns 3 and 4, 
respectively) while ASL-wt transfection yielded 
high enzymatic activity (Fig. 7A: column 5).  
To study the effect of ASL splice variants on the 
function of the ASL homotetramer, and the 
possibility of a heterotetramer formation with 
reduced ASL activity that may contribute to the 
biochemical and clinical variability in ASA 
patients, we measured the ASL activity after co-
transfections. The residual ASL activities in cells 
co-expressing P-wt and P-ex2del (Fig. 7B,C: 
column 2) or co-expressing P-wt, P-ex2del and 
P-ex7del (Fig. 7B: column 4) showed a 
significant decrease to 62.5±7.2% or 55.5±7.2% 
(mean±SD), respectively, of cells co-transfected 
with P-wt and EV (Fig. 7B,C: column 1 and 
Table 1). Cells co-transfected with P-wt and P-
ex7del (Fig. 7B,C: column 3) displayed no 
decrease of ASL activity (94.2±9.4% of ASL 
wt). Cells co-transfected with P-ex2del and P-
ex7del (Fig. 7B: column 5) showed no relevant 
residual ASL activity. Furthermore, the reduced 
level of residual ASL activities exhibited no 
significant difference between cells co-
expressing P-wt and P-ex2del and cells co-
expressing P-wt, P-ex2del and P-ex7del (Fig. 
7B: column 4). Interestingly, cells expressing 
only the ASL mutant P-E189G had a similar 
level of ASL-wt activity (Fig. 7C: column 4) but 
cells co-expressing P-wt and P-E189G showed 
two-folds levels of wt activity (Fig. 7C: column 
7). However, the residual activity in cells co-
transfected with P-E189G and P-ex2del or co-
transfected with P-E189G and P-ex7del (Fig. 
7D: column 5 or 6) exhibited a significant 
decrease to 16.6±5.3% or 57.5±3.2% 
(mean±SD), respectively, of cells co-transfected 
with P-wt and EV (Table 3). These findings 
indicate that the truncated protein caused by 
deletion of ASL exon 2, although showing no 
relevant residual activity, has a dominant 
negative effect on the ASL activity after co-
expression with P-wt or P-E189G. In contrast, 
deletion of exon 7 seems to have no significant 
effect on ASL-wt activity after co-expression 
with P-wt, since it probably forms an unstable 
protein according to Western Blot analysis (Fig. 
3C-E,G) and computational predictions (Fig. 5C, 
6G-H), but has nevertheless a potential dominant 
negative effect on ASL mutant activity after co-
expression with P-E189G (Fig. 7C: column 6).  
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In order to further assess whether the negative 
effect of the simultaneous expression of ex2del 
mutant on ASL-wt is dose-dependent in vitro, 
we performed transient co-transfections with P-
wt and P-ex2del at different ratios 1:1, 1:2, 1:5, 
2:1 or 5:1. The co-expression of ASL-wt and 
ASL-ex2del at above different ratios could be 
detected by Western Blot analysis (Fig. 3F). In 
cells co-expressing ASL-wt and ASL-ex2del 
with higher proportion of mutant DNA, we 
observed a significant gradual decrease of ASL-
activity when compared with cells co-expressing 
wt and EV (Fig. 7D). Moreover, cells co-
expressing ASL-wt and ASL-ex2del with higher 
proportion of wt DNA showed a significant 
gradual increase of ASL-activity (Fig. 7D). 
These findings indicate that the negative effect 
of ASL-ex2del on the wt activity is dose-
dependent.   
 
 
Discussion 
 
To date, the mechanism of the broad 
biochemical and clinical heterogeneity in ASA 
patients still remains to be fully explained as it is 
not just the result of different genotypes. 
Possible hypotheses include ASL tissue specific 
expression (27-28), genetic variability (29) and 
intragenic complementation at the ASL locus 
(7,30-32), the DNA methylation status (35) and 
the frequent occurrence of alternative ASL 
splicing variants (5,36-37). In addition, several 
hormones such as glucocorticosteroids and 
insulin influence the regulation of ASL mRNA 
(52). Recently, a complex formation with the 
enzymes argininosuccinate synthetase and nitric 
oxide synthase required for nitric oxide synthesis 
was described (2), adding further to the 
complexity of this, obviously not only, urea 
cycle enzyme. In the present study, we were 
interested in the tissue-dependence of ASL 
transcript variants and their role for the clinical 
and biochemical phenotype in ASA. 
RT-PCR yielded comparable expression levels 
for the detected transcript variants in 17 different 
human tissues (Fig. 2) suggesting that the 
expression of transcript variants is not tissue-
dependent. These findings are consistent with 
earlier reports, in which full-length ASL 
expression was studied in 11 different human 
tissues (53) and with previous reports on the 
frequent skipping of exons 2 or 7 (5,36).  
However, it remains pivotal to understand 
whether the frequent transcript variants in this 
gene indeed play a role in ASA patients at 
physiological levels or if present at higher 
concentrations. To do so, we further investigated 
the expression levels of transcript variants as 
well as their enzymatic characteristics in vitro. 
Establishment of an ASL expression system in 
293T cells (Fig. 3A) allowed us to investigate 
the ASL activities after ectopically expressing or 
co-expressing ASL-wt and one ASL mutant 
(p.Glu189Gly) or/and splicing variants. 
Immunoblotting showed non-detectable ASL 
expression in cells transfected with the ex7del 
construct (Fig. 3C-E,G) yielding unchanged 
ASL activity levels after co-expression of ASL-
wt and ASL-ex7del (Fig. 7B,C and Table 1), but 
having a potential dominant negative effect on 
the ASL mutant activity after co-expression of 
ASL mutant p.Glu189Gly and ASL-ex7del (Fig. 
7C and Table 3). Moreover, the observation of a 
2-fold increase in the ASL activity after co-
expressing P-wt and P-E189G (Fig. 7C: column 
7) further supports the view that the negative 
effect on ASL mutant activity in cells co-
transfected with P-E189G and P-ex7del is not 
caused by the mutant itself. Computational 
structure modelling revealed that ex7del variant 
was capable to form a monomeric structure with 
three distinct domains, similar to that of ASL-wt 
(Fig. 5C). As predicted by structural analysis, 
ex7del may interfere with tetramer formation 
and seriously impact the stability of the core 
monomeric structure (Fig. 5), leading to 
premature degradation of the monomers. This 
may explain the undetectable ASL-exdel7 
monomers after co-expression with ASL-wt or 
with p.E189G (Fig. 3D,G). Nevertheless, the 
ex7del ASL monomer may still form a 
heterotetramer with other monomers before 
degradation occurs, especially with easily 
accessible mutants such as p.Glu189Gly, which 
then would result in reduced ASL activity. It 
should be noted that exon 7 contains 78 bases 
allowing formation of an in-frame mutant ASL 
protein (5). This finding is somewhat different to 
an earlier study (54), in which a small amount of 
a 49-kDa band in addition to the expected ASL-
wt band on Western blots was speculated as 
exon 7 skipping product that may be due to 
proteolysis (5). However, the details of the 
possible degradation of ex7del ASL were not 
investigated in this study.  
Although exon 2 skipping was observed in 
previous studies (29,36), these authors didn’t 
determine the molecular basis and impact for 
this deletion. As one of the main findings of our 
investigations, we could show that exon 2-
spliced ASL can form a stable truncated protein 
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(Fig. 3C-G) but it lacks any relevant activity 
(Fig. 7A; Table 1). This finding is consistent 
with our prediction explored by computational 
structure modelling that exon 2 is in close 
vicinity to the active site (Fig. 6B,C) and its 
deletion is probably deleterious. Surprisingly, 
this stable truncated mutant protein has a 
dominant negative effect on the ASL activity 
after co-expressing ASL-wt as well as ASL-
p.Glu189Gly with ASL-ex2del (Fig. 7B,C); in 
the latter case, this was even more relevant. 
Furthermore, this negative effect is ASL-ex2del 
DNA dose-dependent (Fig. 7D). The reduced 
ASL activity may result from the formation of a 
heterotetramic structure between ASL-wt and 
ASL-ex2del mutant protein as well as 
homotetrameric ex2del variants that are 
enzymatically inactive, competing for the 
substrate, depending on their proportions. Since 
three different subunits of ASL contribute to the 
active site in the tetrameric structures, different 
combinations of wt and ex2del variant subunits 
may combine to form tetramers with 3, 2, 1 or 0 
active sites. It is possible that proteins of 
different size resulting from wt or exon 2 deleted 
transcripts may have a preference for each other 
when forming the dimeric units before joining to 
form tetramers. In such a scenario only 2:2 
versions of the heterotetramers may be the 
preferred assembly in addition to the fully 
functional and non-functional molecules with 4 
or 0 active sites. Due to a lack of liver samples 
derived from ASA patients, we could not show 
whether a different amount of ASL-ex2del 
mutant protein is expressed in the ASA patients, 
which may interact with ASL-wt to form a 
heterotetramer leading to different level of 
residual ASL activity.  
While this study clearly shows that transcript 
variants under physiological conditions are only 
present at low concentrations (Fig. 2A-D), the 
situation was found different in two patients 
affected by late onset ASA (Fig. 2C: lanes 2 and 
3; Fig. 1D: lane 16). Both patients were shown 
to carry the same known ASL missense mutation 
(p.Glu189Gly) with low residual ASL activity in 
red blood cells found in one of the patients (25), 
absent activity after bacterial overexpression 
(33) but significant residual activity in yeast 
experiments (55). While the mutation was found 
in a heterozygous state by genomic DNA 
sequencing, the level of the ASL-ex7del 
transcript variant observed by RNA studies was 
much higher (Fig 2C: lanes 2 and 3; Fig. 2D: 
lane 16). Under standard PCR conditions (38 
cycles), no full-length ASL transcript was 
amplified, but a faint full-length band was 
detected after 42 PCR cycles indicating the low 
expression of this transcript. Sequencing 
confirmed the mutation c.566A>G in a 
hemizygous state in one patient (Fig. 2E) 
suggesting that the ASL wt allele in this 
particular patient is completely subject to 
alternative splicing and hence, no wt transcript is 
expressed while in the other patient 
heterozygosity was found (Fig. 2F). We suggest 
here that the high expression level of the ASL-
ex7del variant contributed to the ASA phenotype 
in the patients in addition to the missense 
mutation. From the finding in these patients we 
deduce that the same phenomenon may play a 
role also in other patients possibly affected by 
any of the transcript variants (such as patient 16 
in (25) with no mutation found but skipping of 
exon 5).   
In conclusion, this study suggests that transcript 
variants of ASL exist at high frequency in 
different tissues and play a role for the clinical 
and biochemical variability in ASA patients in 
whom they are expressed at high levels. If this 
occurs with an increased expression level of a 
stable expressed truncated variant such as ASL-
ex2del variant, the effect may be even more 
prominent since the likelihood of stable mutant 
homo- or heterotetramer formation increases 
impairing overall ASL activity. Although the 
unstable splice variant ASL-ex7del has no effect 
on ASL-wt activity, it shows likely a dominant 
negative effect on ASL mutant activity. The 
findings from this study expand our knowledge 
of the molecular background in ASA patients 
rendering further studies into transcript variants 
necessary, especially in patients with no or only 
single mutations. 
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Figure legends 
 
Figure 1: Involvement of argininosuccinate lyase in various metabolic and biochemical 
pathways 
Schematic illustration of the involvement of ASL in various metabolic and biochemical reactions. 
Colours are used to show the affiliation of metabolites and enzymes to different pathways: blue, urea 
cycle; golden, nitric oxide synthesis; bordeaux, polyamine synthesis; purple, creatine synthesis. 
Enzymes are depicted in ovals: ADC, arginine decarboxylase; AGAT, arginine:glycine 
amidinotransferase; ARG, arginase; ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase; 
CPS1, carbamoylphosphate synthetase 1; GAMT, guanidinoacetate methyltransferase; NOS, nitric 
oxide synthase; ODC, ornithine decarboxylase; OTC, ornithine transcarbamylase.  
 
Figure 2: Occurrence of transcript variants of the ASL gene in different tissues 
PCR products representing short fragments of ASL cDNA from 16 different tissues (panel A), from 
cultured skin fibroblasts derived from 12 ASA patients (panel B), from lymphocytes derived from two 
ASA patients and one patient’s mother (panel C) and from controls’ lymphocytes, livers and 
fibroblasts as well as lymphocytes derived from one ASA patient and his mother (panel D). A: lane 1-
16: 1, skin fibroblast; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas; 
9, spleen; 10, thymus; 11, prostate; 12, testis; 13, ovary; 14, small intestine; 15, colon; 16, peripheral 
leukocytes. B: lane 1-12 (obtained from three different investigations): skin fibroblasts from 12 ASA 
patients with 10 different genotypes. C: lane 1-4: 1, mother of patient in lane 2; 2-3, two ASA 
patients; 4, control. D: lane 1-15: 5 controls’ lymphocytes (lane 1-5), livers (lane 6-10) and fibroblasts 
(lane 11-15); lane 16: lymphocytes from one patient (same patient as in Fig. 2C lane 2); lane 17: 
lymphocytes from mother of patient in lane 16 (same as in Fig. 2C lane 1). E: Sequencing 
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chromatogram of PCR product from lane 2 in Fig. 2C. F: Sequencing chromatogram of PCR product 
from lane 3 in Fig. 2C. M: peqGOLD 100 bp DNA ladder plus (Peqlab, Erlangen, Germany); M’: 100 
bp DNA ladder (Solis BioDyne, Tartu, Estonia). Gel electrophoresis was done in 1% agarose.  
 
Figure 3: Expression or co-expression of ASL wildtype and transcript variants in different 
mammalian cell lines and human livers 
Western blot analysis of ASL expression in cell extracts of COS-1, 293T and HeLa cells (A), in 
human livers (B) or in transfected 293T cells (C-G). 30 µg of total protein was separated by 10% 
SDS-PAGE (A-B, D, F-G and upper panel in C) or by native PAGE (E and middle panel in C) for 
analysing ASL expression. A: NT, non-transfected; EV, empty vector pcDNA3; wt, pcDNA3-ASL-wt 
(P-wt). B: lane 1-3: human liver samples from 3 controls. C: ASL expression in 293T cells non-
transfected (NT) or transfected with EV, P-wt, pcDNA3-ASL-ex2del (P-ex2del) or pcDNA3-ASL-
ex7del (P-ex7del), respectively. D: (Co)-expression of ASL monomers in 10% SDS-PAGE (ASL-wt: 
52 kDa, ASL-ex2del: 45 kDa). Lane 1-7: 1, P-wt with EV; 2, P-wt with P-ex2del and EV; 3, P-wt 
with P-ex7del and EV; 4, P-wt with P-ex2del and P-ex7del; 5, P-ex2del; 6, P-ex7del; 7, EV. E: (Co-) 
expression of ASL homotetramers in 10% native PAGE (ASL-wt: ~200 kDa, ASL-ex2del: ~180 
kDa). Lane 1-7 same as in D. Asterisks indicate unspecific bands. F: ASL expression in 293T cells 
co-transfected with P-wt and P-ex2del at different ratios. Lane 1-9: 1, P-wt (1.75 µg); 2, 1:1; 3, 1:2; 4, 
1:5; 5, P-wt (3.5 µg); 6, 2:1; 7, P-wt (8.75 µg); 8, 5:1; 9, ASl-ex2del (3.5 µg). G: (Co)-expression of 
ASL mutant p.Glu189Gly (P-E189G) with transcript variants. Lane 1-9: 1, P-wt with EV; 2, P-E189G 
with EV; 3, P-wt with P-E189G; 4, P-wt with P-ex2del; 5, P-wt with P-ex7del; 6, P-E189G with P-
ex2del; 7, P-E189G with P-ex7del; 8, P-ex2del; 9, P-ex7del. Asterisks indicate unspecific bands. β-
actin (42 kDa) and GAPDH (37 kDa) served as loading control.  
 
Figure 4: Positions of exons 2 and 7 in secondary structure of the ASL protein  
The helices are in yellow, sheets in green and turns in cyan; exons 2 and 7 are depicted in magenta. 
Amino acids are colored based on their chemical properties with aspartic and glutamic acid in red, 
arginines and lysines in blue and aromatic amino acids in green. 
 
Figure 5: Monomeric structure of wildtype and models of ASL exon 2- or exon 7-deleted 
transcript variant  
A: Monomeric structure of wt ASL. ASL monomer has three distinct subdomains, domains 1 and 3 
have similar structure and topology with two helix-turn-helix motifs in perpendicular arrangement. 
Domain 2 has nine helices and five of them form the central five helix bundle with up-down-up-
down-up topology. B: Monomeric structural model of ex2del ASL. Two critical helices that are part 
of domain 1 (indicated by black arrow) and contribute to the active site are missing in the ex2del 
variant of ASL. C: Monomeric structural model of ex7del ASL. Exon 7 residues are part of domain 2 
in the ASL monomer comprising the central five helix bundle. Deletion of exon 7 results in a 
disordered central core with one of the five central helices partially replaced by an unstructured loop 
(indicated by black arrow). N, N-terminus; C, C-terminus. 
 
Figure 6: Tetrameric structure of wildtype and models of ASL exon 2- or exon 7-deleted 
transcript variant   
A: Tetrameric structure of wt ASL showing the positions of active site histidine 160 and exons 2 and 
7. Structure is shown as a ribbons model in light blue, amino acids contributed by exon 2 are colored 
in red, while amino acids contributed by exon 7 are colored in magenta. The active site residues are 
colored in green with H160 at the catalytic center shown a sphere model. B: Location of exon 2 in 
relation to active site. In the ASL homotetramer active site residues are contributed by three different 
subunits. ASL structure is shown as a ribbons model with different subunits colored in green, cyan, 
magenta and yellow. The green and cyan subunits form a dimer and join with another dimer formed 
by magenta and yellow subunits to form the tetramer. Active site residues from one of the sites are 
shown as solid surfaces while catalytic center (H160) is shown as spheres. Residues contributed by 
exon 2 are shown in red. C: The role of N-terminus tail in stabilizing the active site. The ASL 
homotetramer is shown as a solid surface model with different subunits colored in green, cyan, 
magenta and yellow. Residues contributed by exon 2 are shown in red. The N-terminus tail surrounds 
the active site and provides the stability required for binding of substrate. D: Conjectural prediction of 
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exon2 deleted ASL based on homology modelling. The core structure of ASL homotetramer can still 
be formed in the absence of N-terminus residues contributed by exon 2. The model of exon2del 
tetrameric complex is similar to the wt ASL and central four-helix bundle comprising the tetramer 
remain intact, resulting in a stable structure. However, the loss of N-terminus required for substrate 
binding will result in an enzymatically inactive protein. E: The wt ASL tetramer structure showing 
the locations of residues contributed by exon 7. The homotetramer structure is shown as a ribbons 
model with different subunits colored in green, cyan, magenta and yellow. The amino acids 
contributed by exon 7 are shown as surface models in two of the adjacent dimeric structures that form 
the tetramer. Chains shown in green and yellow are from two different dimers that join together to 
form the tetramer. The H160 residue at the catalytic centre is shown as spheres. F: A spacefilled 
surface model of homotetrameric ASL structure showing the role of exon 7 in tetramer formation. 
Interactions between charged residues on adjacent dimeric ASL subunits stabilize the tetrameric 
structure. G: A structural model of exon 7 deleted variant of ASL transcript. One subunit of exon 7 
deleted variant is superimposed on the wt ASL homotetramer to show the structural differences. The 
protein is shown as ribbons model with exon 7 deleted variant colored in grey, while wt subunits in 
tetramer are colored in green, cyan, magenta and yellow. The residues involved in charge based 
interaction located on two adjacent subunits in the wt protein are shown as sticks in the larger oval red 
dotted box. The secondary structure elements altered in the exon 7 deleted variant are marked in 
smaller oval box. H: A closeup of the structural changes resulting from the exon 7 deletion. Exon 7 
deleted variant (grey) and wt (green) are superimposed and residues contributed by exon 7 in the wt 
protein are shown in red. Two of the central helices in the wt protein are altered to flexible loops in 
the exon 7 deleted variants, resulting in an unstable protein due to requirement of core helices in the 
domain 2 of the ASL monomers for the overall stability. The resultant protein was found to be highly 
unstable and unlikely to participate in tetramer formation.  
 
Figure 7: Analysis of recombinant ASL activities  
ASL enzymatic activity analysis in non-transfected or (co)-transfected 293T cell extracts. Each 4.8-14 
µg total protein of cell extracts was used for the enzyme assay. The residual ASL activities are 
represented in percentage of ASL-wt activity (% of ASL-wt or % of ASL-wt with EV). A: 293T cells 
were transiently transfected with 7 µg of P-wt (wt), P-ex2del (ex2del) or P-ex7del (ex7del), 
respectively. NT: non-transfected; EV: empty vector. Non-transfected cells and those transfected with 
EV served as negative control. B: 293T cells were transiently co-transfected with 10.5 µg of total 
plasmids at a ratio 1:1 (each 3.5 µg) of P-wt to P-ex2del or P-ex7del plasmids, respectively. C:  293T 
cells were transiently co-transfected with 7 µg of total plasmids at a ratio 1:1 (each 3.5 µg) of P-wt to 
P-ex2del or P-ex7del and of P-E189G to P-ex2del or P-ex7del plasmids, respectively. D: ASL 
enzymatic activity in 293T cell extracts co-transfected with P-wt and P-ex2del at different ratios. 3-12 
µg of cell extracts was used for ASL enzyme analysis depending on the amount of P-wt used for the 
co-transfections. For co-transfections different ratios of ASL-wt to ex2del splice variant (1:1, 1:2, 1:5, 
2:1 or 5:1) were used, respectively. The residual activity of each co-transfectant compared with ASL-
wt under the same condition is indicated in percentage of ASL-wt activity (% of ASL-wt co-
transfected with EV to use identical amounts of total plasmids and of P-wt for all experiments). EV 
was used to set up the same amount of total plasmids for the co-transfections. Levels of significance 
are given as p-values obtained by One-way ANOVA using GraphPad software from triplicate 
measurements of at least 3 independent experiments, respectively. Differences were considered as 
significant if p value was < 0.05. 
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Table 1: Residual ASL activities in 293T cells (co-)transfected with recombinant ASL-wt and 
transcript variants  
293T whole 
cell extracts NT EV ex2del ex7del wt 
wt+ 
EV 
wt+EV
+ex2del
wt+EV
+ex7del
wt+ex2del 
+ex7del 
ex2del+ 
ex7del+EV
ASL activity 
in mIE/mg 
total protein 
(mean±SD; in 
triplicate) 
1.2 
± 
1.9 
1.6 
± 
2.2 
3.2 
± 
3.0 
1.9 
± 
1.4 
830.2
± 
78.8 
520.1 
± 
297.5 
307.5 
± 
151.4 
466.1 
± 
232.7 
305.3 
± 
201.7 
3.2 
± 
1.5 
ASL activity  
in     % of 
ASL-wt 
(mean±SD; in 
triplicate) 
0.4 
± 
0.4 
0.3 
± 
0.2 
0.5 
± 
0.4 
0.4 
± 
0.2 
100.0
± 
7.8 
100.0 
± 
2.6 
62.5* 
± 
7.2 
94.2 
± 
9.4 
55.5* 
± 
7.2 
0.7 
± 
0.3 
Data were obtained under standard conditions (13.6 mM argininosuccinate) after at least three 
independent experiments. ASL activity in cells (co-)expressing ASL-wt or ASL-wt with EV is set to 
100% in each transfection (7 µg of plasmid) or co-transfection (total 10.5 µg of plasmids, each 3.5 
µg) under same condition, respectively. Significant differences compared to ASL-wt activity are 
indicated by an asterisk (p<0.05). NT: non-transfected cells; EV: empty vector. 
 
 
Table 2: Computational determination of structural properties of ASL-wt, ASL-ex2del and 
ASL-ex7del proteins 
 ASL-wt ASL-ex2del ASL-ex7del 
Molecular weight 51658 Da 44471 Da 48733 Da 
Theoretical pI 6.04 5.90 5.76 
Solvent accessible surface 322934 Å3 296898 Å3 326476 Å3 
Accessible surface area 53534 Å2 55904 Å2 65259 Å2 
Potential energy -95229 kJ/mol -77219 kJ/mol -76378 kJ/mol 
Radius of gyration 36.3 Å 36.1 Å 36.9 Å 
Electrostatic solvation energy -29769 kJ/mol -24454 kJ/mol -27781 kJ/mol 
Electrostatic potential -14.89 kJ/mol -20.4 kJ/mol -43.07 kJ/mol 
Computational parameters were determined with WHATIF and YASARA. 
 
 
Table 3: Residual ASL activities in 293T cells co-transfected with recombinant ASL-wt, mutant 
p.E189G and transcript variants  
293T whole cell 
extracts 
wt + 
EV 
wt+ 
ex2del
wt+  
ex7del
E189G
+EV 
E189G 
+ex2del
E189G 
+ex7del 
wt+ 
E189G 
mean ASL activity in 
mIE/mg total protein 
(mean±SD) 
450.2   
±      
38.3 
286.1   
±       
5.5 
363.5   
±      
15.0 
389.1   
±      
30.8 
78.4     
±        
26.4 
257.2    
±        
10.5 
883.8    
±        
80.0 
mean ASL activity in 
% of ASL-wt+EV 
(mean±SD) 
100.0   
±       
7.1 
61.9*   
±       
5.8 
88.5    
±      
11.5 
88.4    
±      
11.9 
16.6*    
±        
5.3 
57.5*    
±        
3.2 
197.6    
±        
8.9 
Data were obtained under standard conditions (13.6 mM argininosuccinate) after three independent 
experiments. ASL activity in cells co-expressing ASL-wt with EV is set to 100% in each co-
transfection (total 7 µg of plasmids, each 3.5 µg) under same condition. Significant differences 
compared to ASL-wt activity are indicated by an asterisk (p<0.05). All measurements in triplicate. 
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